Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Debate over the safety of rosiglitazone

A recent study has put the safety of rosiglitazone, a widely used therapy for type 2 diabetes,under the spotlight. The study claims the treatment significantly increases the risk ofmyocardial infarction and that there is a borderline significant increased risk of death fromcardiovascular causes. However, the makers of rosiglitazone €” GlaxoSmithKline €” refutethese findings and say the study has significant limitations. Dawn Powell reviews the issues.

A recent study has put the safety of rosiglitazone, a widely used therapy for type 2 diabetes,under the spotlight. The study claims the treatment significantly increases the risk ofmyocardial infarction and that there is a borderline significant increased risk of death fromcardiovascular causes. However, the makers of rosiglitazone €” GlaxoSmithKline €” refutethese findings and say the study has significant limitations. Dawn Powell reviews the issues.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy